| Dr Robert C Maron, EDD | |
|
10 Chestnut Street, Needham, MA 02492 | |
| (781) 449-1143 | |
| (781) 449-5992 |
| Full Name | Dr Robert C Maron |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 34 Years |
| Location | 10 Chestnut Street, Needham, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023180437 | NPI | - | NPPES |
| W04958 | Other | BCBS | |
| 006095 | Other | TUFTS | |
| 085675 | Other | VALUE OPTIONS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 6095 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maron Dga Pc | 3274784012 | 30 |
News Archive
The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.
A team at the Research Centre for Biomedical Engineering of the Universitat Politècnica de Catalunya has developed an innovative smart lighting system for operating theatres.
MorphoSys AG announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies.
The signs of a cardiac arrest may exist but if you are under insured or not insured there is good chance that you may not undertake the recommended life saving actions of getting professional help as soon as you can.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
› Verified 6 days ago
| Entity Name | Nova Psychiatric Services, P.c |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881782522 PECOS PAC ID: 4183524887 Enrollment ID: O20040109000776 |
News Archive
The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.
A team at the Research Centre for Biomedical Engineering of the Universitat Politècnica de Catalunya has developed an innovative smart lighting system for operating theatres.
MorphoSys AG announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies.
The signs of a cardiac arrest may exist but if you are under insured or not insured there is good chance that you may not undertake the recommended life saving actions of getting professional help as soon as you can.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
› Verified 6 days ago
| Entity Name | Maron Dga Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427146414 PECOS PAC ID: 3274784012 Enrollment ID: O20121105000023 |
News Archive
The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.
A team at the Research Centre for Biomedical Engineering of the Universitat Politècnica de Catalunya has developed an innovative smart lighting system for operating theatres.
MorphoSys AG announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies.
The signs of a cardiac arrest may exist but if you are under insured or not insured there is good chance that you may not undertake the recommended life saving actions of getting professional help as soon as you can.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
› Verified 6 days ago
| Entity Name | Dana Behavioral Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427731256 PECOS PAC ID: 8123474657 Enrollment ID: O20231019002412 |
News Archive
The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.
A team at the Research Centre for Biomedical Engineering of the Universitat Politècnica de Catalunya has developed an innovative smart lighting system for operating theatres.
MorphoSys AG announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies.
The signs of a cardiac arrest may exist but if you are under insured or not insured there is good chance that you may not undertake the recommended life saving actions of getting professional help as soon as you can.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert C Maron, EDD 10 Chestnut Street, Needham, MA 02492 Ph: (781) 449-1143 | Dr Robert C Maron, EDD 10 Chestnut Street, Needham, MA 02492 Ph: (781) 449-1143 |
News Archive
The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.
A team at the Research Centre for Biomedical Engineering of the Universitat Politècnica de Catalunya has developed an innovative smart lighting system for operating theatres.
MorphoSys AG announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies.
The signs of a cardiac arrest may exist but if you are under insured or not insured there is good chance that you may not undertake the recommended life saving actions of getting professional help as soon as you can.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
› Verified 6 days ago
Sara Orozco, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 5 Alfreton Rd, Needham, MA 02494 Phone: 617-877-2941 | |
Thomas Francis Harrington, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 16 White Pine Rd, Needham, MA 02492 Phone: 781-444-2873 Fax: 781-444-2873 | |
Dr. Michelle Lynn Avigan, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 1040 Great Plain Ave, Suite 101, Needham, MA 02492 Phone: 781-856-8727 Fax: 781-449-3134 | |
Dr. Eric Endlich, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 77 Ardmore Rd, Needham, MA 02494 Phone: 617-515-3568 | |
Dr. Mark H. Keeler, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 687 Highland Ave, Needham, MA 02494 Phone: 617-254-3800 Fax: 617-779-1482 | |
Dr. Mitchell Raymond Abblett, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 10 Chestnut St, Needham, MA 02492 Phone: 781-449-1143 |